Medical organizations across the country are trending toward patient-centered care, incorporating meaningful patient activation and engagement (PAE) into their clinical routines. But, despite a push for more personalized medicine, the majority of physicians and assistants still fail to fully understand what PAE means, and much less how to incorporate it into practice.

Faced with the threat of regulations and accusations of targeting minors with vaping products and marketing, Juul Labs announced Nov. 13 it would suspend retail sales of most of its flavored e-cigarette pods and shut down social media promotions.

A miniature pacemaker developed for use in infants and those with limited vascular access has passed a proof-of-concept simulation and is entering its second phase of testing, researchers from Children’s National Health System in Washington, D.C., have reported.

Cancer is overtaking heart disease as the leading cause of death in the U.S., particularly in high-income counties, suggests a new analysis published in the Annals of Internal Medicine.

A third blood pressure drug has been recalled over a carcinogenic impurity, the FDA announced Nov. 8.

Physicians who have financial relationships with biomedical manufacturers are up to 12 times more likely to use an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) from that company instead of another manufacturer, according to preliminary research presented at the American Heart Association Scientific Sessions in Chicago.

A new study aims to evaluate whether medical professionals with no ultrasound experience can use artificial intelligence (AI) software to capture high-quality echocardiograms, potentially opening the door to greater testing in primary care settings.

DUBLIN - November 13, 2018 - Medtronic plc (NYSE:MDT) today announced it has received CE Mark approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), blunt traumatic aortic injuries (BTAI), penetrating atherosclerotic ulcers (PAU), intramural hematomas (IMH), and type B aortic dissections (TBAD). This news also follows the recent U.S. FDA approval of the Valiant Navion system.

CHICAGO, Nov. 11, 2018 — Developing novel approaches to understand cardiovascular health and pre-disease is the cornerstone strategy of One Brave Idea™, a research initiative led by Dr. Calum MacRae, vice chair for Scientific Innovation in the department of Medicine at Brigham and Women's Hospital.

The Door-to-Unload pilot study concluded without any “prohibitive safety signals,” researchers reported at the American Heart Association 2018 Scientific Sessions, clearing the path for a larger trial to test the hypothesis that ventricular unloading prior to PCI with the Impella CP heart pump can reduce reperfusion injury.